Trial results

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471 on ClinicalTrials.gov · last registry update 2026-08-21

Recruiting now, toward 800 participants. Due to report April 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score. Sponsors move these dates routinely; any movement since this site started watching is listed below. orforglipron is approved in the US, but not for osteoarthritis — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

RECRUITING

Phase

P3

Drug

orforglipron

Foundayo

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

800

Started

2025-09-15

Primary completion

2028-04 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score

Conditions studied

Osteoarthritis

Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.